G-Theranostics, Inc. (Tokyo, Japan) and Sudy & Co., Ltd. (Budapest, Hungary) hereby announce that we will jointly serve as the primary liaison for co-development, licensing, and investment engagements across Japan and Asia for biotech company VRG Therapeutics (Budapest, Hungary).

Under mutual NDAs, we will initiate exploratory discussions with pharmaceutical and biotech companies, healthcare institutions, and investors, and support partnership structuring, including collaboration, licensing, and equity/JV arrangements. Please note that no exclusive sales agency (Sole Agent) arrangement is in place at this time. We will propose fit-for-purpose collaboration structures on an opportunity-by-opportunity basis.

Parties (HQ): VRG Therapeutics (Budapest, Hungary); G-Theranostics, Inc. (Tokyo, Japan); Sudy & Co., Ltd. (Budapest, Hungary — Tokyo, Japan).

Company Snapshots:

VRG Therapeutics (Budapest, Hungary)

VRG’s mission is to cure diseases by addressing targets and mechanisms of action that cannot be reached with traditional approaches. The company is advancing its pipeline in the autoimmune space through its proprietary AI-powered drug discovery platform, AI-MPRO, focusing on Kv1.3, IL-6, and IL-11 targets. VRG’s senior advisors include Sagar Khare, who previously worked at the University of Washington with Prof. David Baker, recipient of the 2024 Nobel Prize in Chemistry for his contributions to computational drug design.

Website: https://lnkd.in/eUviaTeb

Sudy and Co., Ltd. (Budapest, Hungary — Tokyo, Japan)

Sudy & Co., Ltd. is a consulting firm founded in 2000 that specializes in bridging Asian and Central & Eastern European businesses through services such as market research, market entry support, sales support, crossborder M and A-related services and intercultural trainings.

Website: https://sudy.co.hu/en

G-Theranostics (Tokyo, Japan)

• Quantum Viewer™ — an AFM-extension + AI platform that uses AI to capture quantum-scale phenomena, enabling dynamic time-resolved analysis at the nanoscale (ps–ns) and converting conventional 2D signals into multi-dimensional fingerprints; delivered as an integrated package of instrument (AFM extension) and AI software.

• Supersulfide (RSS) program — advancing GSSSG and related supersulfide chemistry toward preclinical applications; patent for supersulfide MS stabilization; translational collaboration with Shimadzu.

• Venture bridge (life science) — connecting 50–100-person overseas biotechs to Japan for licensing and co-development; track record includes ACT Genomics (JV → sold to Canon Medical) and Bio-Xcelerator ( BC Platform’s Japan master agent → sold to NTT). Currently co-leading Japan/Asia engagement for VRG Therapeutics.